BIOMAT Database Logo BIOMAT Database Logo

[Chemotherapy with cisplatin, adriamycin, etoposide and ifosfamide in microcytic lung carcinoma]. 1992

R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Servicio de Oncología Médica, Hospital General Gregorio Marañón, Madrid.

BACKGROUND The aim of this study was to analyze the results obtained in the treatment of small cell lung cancer (SCLC) with the PAVI chemotherapy protocol (cisplatin, adriamycin, etoposide and ifosfamide). METHODS Over a period of 3 years, 41 patients with a mean age of 57 years were treated. Twenty-two patients were considered as having limited disease (LD) and 19 disseminated disease (DD). Survival was studied by the Kaplan and Meier method. RESULTS The percentage of complete response (CR) achieved was 42%, LD 52% and 27% for DD, with partial responses (PR) being achieved in 50%, 43% in LD and 60% in DD. With a mean follow up of 32 months, the mean 2 length of response was 13 months in the patients with CR and 9 months in those with PR. The median of survival in LD was 22 months and 10 months for patients with DD. Prolonged survival of over 2 years, was only achieved in LD (16%). Five patients died in relation with the treatment. Hematologic toxicity was doses-limited with the greatest toxicity being found in patients with DD under the Karnofsky index (KI). CONCLUSIONS The PAVI protocol is effective in the treatment of small cell lung cancer and a good median of survival may be achieved in patients with limited disease. Toxicity is elevated and is fundamentally found in patients with disseminated disease and under the Karnofsky index, with its use not being recommended in these cases.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.
February 2004, The Annals of pharmacotherapy,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
[Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
June 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
[Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer].
November 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
[Adriamycin, cisplatin and etoposide combination chemotherapy in non-small cell lung cancer].
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma.
October 1990, American journal of clinical oncology,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma.
March 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Combined chemotherapy with ifosfamide and cisplatin and with ifosfamide and etoposide (VP-16) in non-small cell carcinoma of the bronchus.
September 1983, Cancer treatment reviews,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma.
December 1988, Nihon Sanka Fujinka Gakkai zasshi,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
December 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R García Gómez, and R García Arroyo, and A Meana García, and P Martínez del Prado, and R González del Val, and G Pérez Manga
[Advanced and recurrent gastric carcinoma: combination chemotherapy with etoposide (E), adriamycin (A), cisplatin (P) = EAP].
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!